CMS Releases the 2019 OPPS and ASC Payment System Final Rule

Holland & Knight LLP
Contact

Holland & Knight LLP

HIGHLIGHTS:

  • The Centers for Medicare & Medicaid Services (CMS) has issued the Calendar Year (CY) 2019 Final Rule that updates payment rates and policy changes in the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System.
  • Significant finalized policies include a proposal to expand Medicare reimbursement cuts for drugs purchased through the 340B discount program to certain hospital off-campus provider-based departments (PBDs), as well as a policy focusing on site-neutral payments for clinic visits at off-campus PBDs. CMS is not finalizing its proposal regarding the expansion of clinical families of services at excepted hospital outpatient departments.

The Centers for Medicare & Medicaid Services (CMS) on Nov. 2, 2018, issued the Calendar Year (CY) 2019 Final Rule that updates payment rates and policy changes in the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System. It is scheduled to be published in the Nov. 21, 2018, issue of the Federal Register and will become effective on Jan. 1, 2019.

Visit the CMS website for the OPPS and ASC Payment System Fact Sheet.

Among significant policies:

  • 340B Drug Payment Policy Applied to Non-Excepted Off-Campus Provider-Based Departments (PBDs): CMS finalized a proposal to expand Medicare reimbursement cuts for drugs purchased through the 340B discount program to certain hospital off-campus departments, focusing Medicare cuts on non-grandfathered hospital outpatient departments (HOPDs) – equal to the 22.5 percent reductions (77.5 percent of Average Sales Price rather than 106 percent of Average Sales Price). Critical Access Hospitals (CAHs), Rural Sole Community Hospitals (SCHs), Children's Hospitals and PPS-Exempt Cancer Hospitals remain excluded from the payment adjustment.
  • Site-Neutral Payments for Clinic Visits at Off-Campus PBDs: CMS finalized a policy to "control unnecessary increases in the volume of covered HOPD services" by paying the Medicare Physician Fee Schedule (MPFS)-equivalent for the clinic visit services when provided at an off-campus PBD paid under the OPPS. This reduction in payment will now be phased in over two years. CY 2019 will see a 30 percent payment reduction for clinic visit G0463 (at all off-campus HOPDs), with an additional 30 percent reduction set for 2020. The American Hospital Association (AHA) and other hospital groups are likely to bring forward another lawsuit on this issue, but it may take years to see any resolution, not unlike what hospitals are facing with the 340B issue.
  • Expansion of Clinical Families of Services at Excepted Off-Campus HOPDs: CMS is not finalizing its proposal regarding "clinical families of services" but will continue to monitor the expansion of services in excepted off-campus PBDs.

It is clear that CMS is interested in further payment equalization between HOPDs and physician offices, increasing the likelihood of further reductions for off-campus HOPDs in the future.

Additional Highlights

HOPD Payment Updates: CMS finalized a 1.35 percent increase in the OPPS conversion factor (CF), higher than the 1.25 percent increase in the proposed rule. CMS anticipates that the CY 2019 CF update, along with changes in enrollment, utilization and case-mix, will result in total payments of approximately $74.1 billion to HOPD providers, an increase of approximately $5.8 billion from CY 2018 payment estimates. HOPDs failing to meet quality-reporting requirements will continue to receive a 2.0 percent reduction in payments for OPPS services.

ASC Payment Updates: For ASCs meeting quality reporting requirements under the Ambulatory Surgical Center Quality Reporting (ASCQR) program, CMS finalized a 2.1 percent increase (higher than the 2.0 percent increase in the proposed rule), based on a projected Consumer Price Index for All Urban Consumers (CPI-U) update of 2.9 percent minus the 0.8 percentage-point multifactor productivity (MFP) adjustment required by the Affordable Care Act (ACA). CMS estimates that this update will result in approximately $4.85 billion in total payments to ASCs. CMS states that more competitive ASC rates could increase patient access to ASCs by prompting those facilities to open in markets that have few or no ASCs so far.

Wholesale Acquisition Cost (WAC)-Based Payment for Part B Drugs: CMS finalized a proposal (similar to the finalized policy in the MPFS) to reduce payment for Part B drugs and biologics that do not report Average Sales Price (ASP), do not receive pass-through payment or are not acquired through the 340B program to WAC plus 3 percent rather than WAC plus 6 percent. If WAC data is not available for a drug or biological, CMS plans to continue its policy to pay separately payable drugs and biological products at 95 percent of the average wholesale price (AWP).

Collecting Data on Services Furnished in Off-Campus Provider-Based Emergency Departments: CMS agreed with the Medicare Payment Advisory Commission (MedPAC) recommendation to develop data to assess the extent to which OPPS services are shifting to off-campus provider-based emergency departments. As a result, CMS in the Proposed Rule announced the implementation of a new claim-line modifier, "ER," that must be billed for outpatient hospital services furnished in an off-campus, provider-based emergency department effective beginning Jan. 1, 2019. The ER modifier would identify items and services furnished by a provider-based off-campus emergency department and would have to be reported with every claim line for outpatient hospital services furnished in an off-campus provider-based emergency department. Critical Access Hospitals are exempt from this requirement.

In the Final Rule, CMS noted that it was not a proposal open to public comment, but nonetheless, it appreciated comments and would consider them in potential future policy development.

Apply 340B Drug Payment Policy to Non-Excepted Off-Campus PBDs: In last year's OPPS final rule, CMS finalized its policy that separately payable, covered outpatient drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B program would be paid at a formula determined by ASP minus 22.5 percent, rather than ASP plus 6 percent, when furnished and billed by a PBD paid under the OPPS. In the Final Rule, CMS finalized a policy to extend this provision to 340B-eligible, off-campus HOPDs that are reimbursed at a lower rate under the MPFS. CMS exempts Rural Sole Community Hospitals, Children's Hospitals and PPS-Exempt Cancer Hospitals from this payment adjustment.

Expansion of Clinical Families of Services at Excepted Off-Campus Departments of a Provider: CMS did not finalize its proposal to reimburse at the MPFS rate (rather than at the OPPS rate) for new items and services from 19 clinical families furnished at an excepted off-campus PBD that were not furnished in a prior, baseline period. Under current regulations, excepted off-campus PBDs can expand their service lines to furnish new items and services and be paid under OPPS rates. CMS noted concerns that this could incentivize hospitals to purchase additional physician practices and expand services furnished by their excepted off-campus PBDs to achieve greater payment under OPPS – therefore undermining the intent of Section 603 of the Bipartisan Budget Act of 2015. While CMS did not finalize its proposal, it stated that it would continue to monitor the expansion of services to excepted off-campus PBDs. Notably, CMS has not finalized this policy over several rulemaking cycles. It is most likely that future rules will continue to tackle this issue.

Site-Neutral Payments for Clinic Visits at Off-Campus PBDs: Last year, CMS found that one procedure code accounted for more than 50 percent of all codes billed at off-campus HOPDs (G0463: hospital outpatient clinic visit for assessment and management of a patient). In order to encourage site-neutral payments across care sites, CMS is finalizing its proposal to pay off-campus PBDs at the MPFS rate for hospital outpatient clinic visits, which use HCPCS code G0463.

CMS' finalized policy means providers who append modifier -PO (excepted service provided at an off-campus, outpatient PBD of a hospital) will be paid a significantly lower rate for G0463 in 2019 than they have been paid previously. The reduction will be phased in over two years and is not budget-neutral.The two years phased payment reduction represents a softening of the proposed approach, because CMS originally desired to implement the 60 percent reduction in payment rates for G0463 in 2019 alone. The new rate would lower the cost of clinic visits from the current $116 with a $23 beneficiary copay to $81 with a $16 beneficiary copay (in 2019), then to a $46 payment and $9 copay in 2020. CMS estimates this policy will lead to approximately $380 million in savings for 2019, with savings to beneficiaries accounting for approximately $80 million of that total. It should also be noted that CMS is concurrently focusing on payment reductions for Evaluation and Management (E/M) services as part of the MPFS. (See Holland & Knight alert, "CMS Releases the 2019 MPFS and QPP Final Rules," Nov. 7, 2018.)

Biosimilars: CMS finalized a policy to pay for biosimilars that don't have pass-through status but are purchased under 340B at the average sales price minus 22.5 percent of the biosimilar's ASP, rather than the ASP of the reference product.

Competitive Acquisition Program (CAP) Request for Information (RFI): CMS received approximately 80 comments relating to the request for information issued in the CY 2019 OPPS/ASC proposed rule that was considered and noted in the recent advance notice of proposed rulemaking (ANPRM) for the International Pricing Index (IPI) model.

Payment for Non-Opioid Pain Management Therapy: CMS finalized its proposal to pay separately at ASP plus 6 percent for non-opioid pain management drugs that function as a supply and when used in a surgical procedure conducted in an ASC. This policy will not apply to hospital outpatient departments, where the products will continue to be packaged in with the payment for the procedure itself.

Changes to PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program: Following additional analyses to assess measure performance using data from the Centers for Disease Control and Prevention (CDC), as outlined in the Fiscal Year (FY) 2019 Inpatient Prospective Payment Systems (IPPS)/Long-Term Care Hospital (LTCH) Final Rule, CMS is not finalizing the removal of two National Healthcare Safety Network (NHSN) measures: Catheter-Associated Urinary Tract Infection Outcome Measure (CAUTI) (NQF No. 0138) and Central Line-Associated Bloodstream Infection Outcome Measure (CLABSI) (NQF No. 0139).

Changes for Inpatient Quality Reporting (IQR) Program: Questions on the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) related to pain communication will no longer be included in a facility's quality rating in response to the opioid crisis. The questions will be removed for discharges on or after Oct. 1, 2019, and will impact payment in FY 2021. Additionally, CMS will not publicly report the three revised Communication about Pain questions.

Changes to Hospital Outpatient Quality Reporting (OQR): CMS finalized its proposal to remove one measure from the program for the CY 2020 payment determination and seven measures for CY 2021.

CMS finalized its proposal to remove the Notice of Participation (NOP) form and OP-27: Influenza Vaccination Coverage Among Healthcare Personal from the program for the CY 2020 payment determination. In CY 2021, a total of seven measures will be removed. CMS did not finalize its proposal to remove the Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients (OP-29) and the Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery (OP-31) measures. CMS also finalized its proposal to extend the performance period to three years for one measure related to hospital visit following colonoscopy (OP-32). CMS also announced plans to change the frequency of the Hospital OQR Program Specifications Manual release beginning with CY 2019.Rather than require its release every six months, the release would occur every 12 months; this is different from the initial proposal of every six to 12 months.

Changes to the Ambulatory Surgical Center Quality Reporting (ASCQR) Program: CMS finalized its proposal to remove one measure from the program for the CY 2020 payment determination and one measure for CY 2021. CMS did not finalize its proposal to remove six measures: Patient Burns (ASC-1); Patient Falls (ASC-2); Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant (ASC-3); All-Cause Hospital Transfer/Admission (ASC-4); Mammography Follow-Up Rates (ASC-9); and Thorax Computed Tomography (CT) Use of Contrast Material (ASC-11) measures. For ASC 1-4, CMS will suspend data collection beginning with the CY 2021 payment determination until further rulemaking with the goal of updating these measures. CMS also finalized its proposal to extend the performance period to three years for one measure related to hospital visit following colonoscopy (ASC-12) and to update the factors CMS will consider when removing measures from the program.

Changes to List of ASC Covered Surgical Procedures: Procedures must be listed on the ASC Covered Procedures List (CPL) to be eligible for reimbursement in the ASC setting. CMS has publicly stated its interest in shifting surgical cases from higher-cost HOPDs to lower-cost ASCs where clinically appropriate. Accordingly, CMS has paved the way for the possible future expansion of the CPL list by expanding the definition of "surgery" in the context of the list. CMS also finalized its proposal to add 12 cardiac catheterization procedures to the list of ASC covered procedures and, in response to comments, five other related procedures. CMS is not finalizing any changes to the ASC CPL after conducting a review of all procedures added within the past three years to reassess whether such procedures should continue to be on the ASC CPL.

Pass-Through Payment Status for Drugs: The pass-through payment status of 23 drugs and biologicals will expire on Dec. 31, 2018, and pass-through payment status will continue for 45 drugs and biologicals. Three additional drugs and biologicals that already have had three years of pass-through will be extended by an additional two years as required by statute. A fourth will have its HCPCS code (Q4172) expire in 2019, but CMS will extend pass-through payment on two of its three successor codes (Q4195 and Q4196).

Payment for Chimeric Antigen Receptor (CAR) T-Cell Therapies: In the Proposed Rule, CMS highlighted that two CAR T-cell therapies were approved by the U.S. Food and Drug Administration (FDA) for transitional pass-through status, effective April 1, 2018. In the Final Rule, CMS is advancing the proposal to continue pass-through payment status for HCPCS code Q2040 (which is being deleted and replaced with HCPCS code Q2042, effective Jan. 1, 2019) and HCPCS code Q2041 for CY 2019.

CMS also proposed four new HCPCS codes for CAR-T therapies. However, none of these new HCPCS codes were proposed to be payable under the OPPS.

Despite stakeholder comments, CMS notes in the Final Rule that it does not believe payment under the OPPS is necessary for procedures described by CPT codes 0537T (harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR T-cells, per day), 0538T (preparation of blood-derived T lymphocytes for transportation) and 0539T (receipt and preparation of CAR-T cells for administration). CMS notes that the existing CAR T-cell therapies on the market were approved as biologics and, therefore, provisions of the Medicare statute providing for payment for biologicals apply. CMS assigned these codes a status indicator of "B" (codes not recognized by OPPS). However, after consideration of public comments, CMS is assigning status indicator "S" (Significant Procedure, Not Discounted When Multiple) to CPT code 0540T (CAR-T cell administration, autologous) and assigning the code to Ambulatory Payment Classification(APC) 5694 for CY 2019.

Pass-Through Payment Status for Devices: This year, CMS received seven applications for pass-through status and approved only one: an implantable system that stimulates a nerve in the chest.

Comprehensive Ambulatory Payment Classifications (C-APCs) and New Technology APC Payment for Low Volume Procedures: CMS finalized its proposal to create three new C-APCs:

  • C-APC 5163 (Level 3 ENT Procedures)
  • C-APC 5183 (Level 3 Vascular Procedures)
  • C-APC 5184 (Level 4 Vascular Procedures)

A new "Smoothing Methodology" for pricing extremely low-volume procedures (which CMS defines as fewer than 100 claims a year under the hospital outpatient payment system) was also finalized.

Under this new methodology, CMS will use up to four years of claims data to set a payment amount for both assigning the service to a New Technology APC but also for assigning the service to a regular APC once it is no longer included in the New Technology APC. Services designated as New Technology APCs will be excluded from bundling into C-APC procedures.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Holland & Knight LLP | Attorney Advertising

Written by:

Holland & Knight LLP
Contact
more
less

Holland & Knight LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.